高通量计算用于检测老年人有害的药物相互作用:基于人口的队列研究协议
Neda Rostamzadeh1, Rishabh Sharma2,3, Sheikh S Abdullah1,2,3,4
1Department of Computer Science, Western University, London, ON, Canada.
JMIR research protocols
|October 10, 2025
概括
本研究使用高通量计算和健康数据,有效地识别老年人有害药物相互作用 (DDI). 这种新的方法旨在提高药物安全性,并为处方实践提供信息.
科学领域:
- 药理流行病学 药理流行病学
- 医疗信息学 医疗信息学
- 老年医学 老年医学
背景情况:
- 药物相互作用 (DDI) 构成重大风险,特别是在服用多种药物的老年人身上.
- 检测有害DDI的传统方法是缓慢的,经常错过关键的相互作用.
- 现有的以人口为基础的研究面临着在鉴定DDI的挑战,因为大量的潜在药物组合.
研究的目的:
- 概述一种用于有效识别老年人有害药物相互作用 (DDI) 的新方案.
- 为了利用行政医疗保健数据进行强大的DDI检测.
- 为更安全的处方实践和监管决策提供信息.
主要方法:
- 开展基于人口的新用户队列研究,使用安大略省链接的行政医疗保健数据 (2002-2023年).
- 利用高通量计算分析了66岁以上的安大略省居民队列.
- 采用倾向性评分方法和回归模型,在30天内评估74个急性结果,控制400多个基线特征.
主要成果:
- 初步分析确定了380万名老年人和500多种独特药物,使研究能够研究大约20万种潜在药物组合.
- 最初的药物对队列中,新用户的中位数为583人,平均重叠时间为57天.
- 该研究协议于2025年8月完成,分析预计将于2026年秋季完成.
结论:
- 这项研究将在常规护理环境中确定老年人有害DDI的可信信号.
- 这种创新方法结合了高通量计算和严格的药物流行病学方法来产生真实世界的证据.
- 预计这些发现将提高药物安全性,并支持明智的临床和监管决策.
相关概念视频
01:15Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
196
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
196
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
234
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
234
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
227
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
227